Mara Memoli

Mara Memoli

Auto-generated profile, based on publicly available information

Mara Memoli

Federico II University Medical School, Naples, Italy

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 May 2019 in Blood Advances
Verified
Journal Article
Open access
PDF file
Marco PicardiMarco Picardi
Marco Picardi
RPRoberta Della Pepa
Roberta Della Pepa
CGClaudia Giordano
Claudia Giordano
NPNovella Pugliese
Novella Pugliese
CMC. Mortaruolo
C. Mortaruolo
FPFabrizio Pane
Fabrizio Pane
We evaluated the impact on progression-free survival (PFS) of achieving a deep metabolic response at 2-deoxy-2[18F] fluoro-d-glucose positron emission tomography (FDG-PET) in patients with refractory or relapsed (R/R) classic Hodgkin lymphoma (cHL) following a new salvage regimen named Bv+Bs (brentuximab vedotin + bendamustine supercharge), from 2013 to 2017. In this real-life study, 20 consecutive patients (aged <60 years) with R/R cHL after failure of ≥1 salvage treatments received Bv+Bs regimen consisting of 3-days outpatient IV infusions of 1.8 mg/kg of Bv on day 1 of each 3-week cycle combined in sequence to bendamustine on days 2 and 3 of the treatment cycle at a fixed dose of 120 mg/m2 per day, for a total of 4 courses. A robust primary prophylaxis approach, including premedication, antimicrobials, stimulating factors, and cytomegalovirus monitoring, was systematically performed. The 20 patients (all evaluable) underwent 4 courses of Bv+Bs with a median dose intensity of 100% for both Bv and Bs. Ten patients (50%) experienced grade ≥3 treatment-related adverse events, without requiring hospitalization. At post-Bv+Bs reevaluation, 80% of patients had deep metabolic responses with Deauville 5-point scale scores ≤2. Thereafter, 14 patients (70%) received autologous hematopoietic stem cell transplantation (HSCT; peripheral blood stem cells previously harvested in 12 cases), and 4 patients (10%) received allogeneic HSCT. At a median follow-up of 27 months from Bv+Bs regimen initiation, the 2-year PFS of the entire population was 93.7% (95% confidence interval, 62.7% to 99.6%). Our data suggest that Bv+Bs regimen-driven strategy may be a promising salvage option to improve long-term control of high-risk Hodgkin lymphoma. Key Points FDG-PET–negative status achieved with salvage therapy is the most important determinant of favorable outcome after HSCT, for patients with R/R cHL. Our modified Bv+Bs salvage regimen led to deep metabolic responses in the majority of patients, establishing a bridge to transplant. Visual Abstract

28 January 2021 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
MMMara Memoli
Mara Memoli
APAnnalisa Paviglianiti
Annalisa Paviglianiti
FMFlorent Malard
Florent Malard
GBGiorgia Battipaglia
Giorgia Battipaglia
EBEolia Brissot
Eolia Brissot
RDRémy Duléry
Rémy Duléry
We assessed the outcomes associated with thiotepa, busulfan and fludarabine (TBF) conditioning regimen in a cohort of 29 consecutive patients allografted for myelofibrosis (MF). The median age was 56 (range 42-70) years. According to the refined Dynamic International Prognostic Scoring System (DIPSS-plus), 15 (52%) patients were classified as high risk. Graft source was peripheral blood stem cells in 27 patients. Donor type was HLA-matched related (n = 5), matched unrelated (n = 16), mismatched unrelated (n = 1), and haploidentical (n = 7). All but 2 patients engrafted. The cumulative incidence (CI) of grade II-IV acute graft-versus-host disease (GVHD) was 21% (95% CI, 10-42) at day 100. The CI of chronic GVHD was 39% (95% CI, 23-65) at 3 years. The median follow-up period was 39 (range 14-60) months. Overall survival was 69% (95% CI, 50-83) at 3 years. No relapse was observed. TBF is a valid conditioning strategy in patients with MF.

11 October 2017 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
OVOrsola Vitagliano
Orsola Vitagliano
FTFabio Trastulli
Fabio Trastulli
FCFabiana Cacace
Fabiana Cacace
SLStefania Leone
Stefania Leone
MMMara Memoli
Mara Memoli
FPFabrizio Pane
Fabrizio Pane

22 May 2025 in Annals of Hematology
Verified
Journal Article
Open access
Francesco GrimaldiFrancesco Grimaldi
Francesco Grimaldi
MMMara Memoli
Mara Memoli
SASimona Avilia
Simona Avilia
RRRoberta Russo
Roberta Russo
GSGiulia Scalia
Giulia Scalia
FPFabrizio Pane
Fabrizio Pane
Progression to Acute Myeloid Leukemia is a well-known complication of classical philadelphia-negative chronic myeloproliferative neoplasms, while disease progression to Acute Lymphoblastic Leukemia remains an extremely unfrequent event. A molecular explanation for this rare phenomenon is missing. However, the clonal haematopoiesis mostly present in these patients may work as a seeding soil for a second neoplastic disease. Molecular results from this case study reporting a secondary Acute Lymphoblastic Leukemia presenting after Essential Thrombocythemia support this hypothesis. In this contest secondary Acute Lymphoblastic Leukemia should not be considered as real blast crisis, but rather as a second cancer determined by a different clonal route. Given the unique features of this case, a review of the published cases of MPN transforming to Acute Lymphoblastic Leukemia available in literature is provided in the article.

26 March 2026 in Annals of Hematology
Verified
Journal Article
Open access
PDF file
RPRoberta Della Pepa
Roberta Della Pepa
ALAldo Leone
Aldo Leone
Francesco GrimaldiFrancesco Grimaldi
Francesco Grimaldi
SASimona Avilia
Simona Avilia
MMMara Memoli
Mara Memoli
FPFabrizio Pane
Fabrizio Pane
Bispecific antibodies targeting B-cell maturation antigen, BCMA (teclistamab) or G protein–coupled receptor, class C, group 5 member D, GPRC5D (talquetamab) are effective treatments for relapsed or refractory multiple myeloma. Their main early toxicity is cytokine release syndrome (CRS), usually transient and limited to initial cycles. We report five patients with relapsed or refractory multiple myeloma who received bispecific antibodies (n = 1 teclistamab; n = 4 talquetamab) who developed a pattern of recurrent, cyclic CRS beyond the initial step-up phase. All patients achieved at least a partial hematologic response, with complete or stringent complete remission in most cases. Recurrent febrile episodes occurred at regular intervals after drug administration, despite repeatedly negative infectious workups. CRS episodes were generally grade 1–2 and resolved with tocilizumab, with or without corticosteroids. In one patient treated with teclistamab, recurrent CRS contributed to treatment discontinuation due to renal complications. Attenuation of CRS severity over time was observed in some patients, allowing treatment continuation with tailored premedication strategies. This case series describes an unusual pattern of recurrent CRS occurring during bispecific antibody therapy for multiple myeloma. Recognition of this phenomenon is essential to avoid misdiagnosis as infection and unnecessary antimicrobial use. Systematic reporting of such real-world adverse events may help refine supportive care strategies.

1 October 2025 in Blood Neoplasia
Verified
Journal Article
Open access
SLStefania Leone
Stefania Leone
Francesco GrimaldiFrancesco Grimaldi
Francesco Grimaldi
MMMara Memoli
Mara Memoli
GSGiulia Scalia
Giulia Scalia
AVAnnamaria Vincenzi
Annamaria Vincenzi
VRValentina Rubino
Valentina Rubino